Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Voyager Therapeutics, Inc. (VYGR)

Voyager Q3 2026 revenue falls to $4.0 million; net loss narrows to $24.7 million

Mixed Impact 3 of 5 earnings Written later

Voyager Therapeutics reported third quarter 2026 results, with collaboration revenue down sharply from a year earlier while its net loss narrowed. The company said its cash runway now extends into the second quarter of 2028, and it expects tau PET imaging data from its VY7523 trial in the fourth quarter of 2026.

Key points

  • Collaboration revenue was $4.0 million for Q3 2026, down from $13.4 million in Q3 2025, mainly due to lower Neurocrine collaboration revenue.
  • Net loss was $24.7 million, or $0.40 per share, versus $27.9 million, or $0.47 per share, in Q3 2025.
  • Research and development expenses fell to $24.4 million from $35.9 million; general and administrative expenses fell to $6.1 million from $8.1 million.
  • Cash, cash equivalents and marketable securities were $132.1 million as of September 30, 2026.

The filing

CompanyVoyager Therapeutics, Inc. (VYGR)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:02 PM ET
Accession number0001193125-26-449728

Items reported: 2.01 Acquisition or Disposition Completed

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.